Relay Therapeutics
RLAY
16.12
+0.21
+1.32%
Relay Therapeutics
US · RLAY
#2273 by market cap
Listed 2020
16.12
+0.21
+1.32%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 126.09% -2.92pp
- Institutions
- 322 +10
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund58.62%
VC/PE Fund35.52%
Hedge Fund15.99%
Public Company14.84%
Individual/Insider1.61%
Private Company0.26%
Government Pension Fund0.25%
Sovereign Wealth Fund0.24%
Family Office/Trust0.19%
Top holders as of 2026-06-30
SB Investment Advisers (UK) Limited
12.63% · 27.90M sh
FMR
10.97% · 24.24M sh
SoftBank Group Corp.
9.91% · 21.90M sh
BlackRock
7.56% · 16.70M sh
Casdin Capital, LLC
7.26% · 16.04M sh
Perceptive Advisors LLC
6.38% · 14.11M sh
Commodore Capital LP
5.43% · 12.00M sh
T. Rowe Price Group, Inc.
4.36% · 9.62M sh
State Street Global Advisors
4.14% · 9.15M sh
Vanguard Capital Management, LLC
4.08% · 9.01M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 13 buys · 37 sells
| Name | Role | Stake |
|---|---|---|
| Sanjiv Patel | Chief Executive Officer | 0.61% |
| Mark Murcko | Founder & Independent Director | 0.45% |
| Donald Bergstrom | President of Research & Development | 0.18% |
| Alexis Borisy | Independent Chairperson | 0.11% |
| Brian Adams | Former Chief Legal Officer | 0.10% |
| Peter Rahmer | Chief Corporate Development Officer | 0.10% |
| Thomas Catinazzo | Chief Financial Officer | 0.05% |
| Douglas Ingram | Independent Director | 0.01% |
| SoftBank Group Corp. | -- | -- |
| Linda Hill | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-27 | Donald Bergstrom | President of Research & Development | Open Market Disposition | -2,252 | $18.62 |
| 2026-10-27 | Peter Rahmer | Chief Corporate Development Officer | Open Market Disposition | -753 | $18.62 |
| 2026-10-27 | Thomas Catinazzo | Chief Financial Officer | Open Market Disposition | -1,469 | $18.62 |
| 2026-10-06 | Sanjiv Patel | Chief Executive Officer | Automatic Disposition | -48,199 | $18.10 |
| 2026-10-05 | Thomas Catinazzo | Chief Financial Officer | Automatic Disposition | -17,717 | $18.58–19.26 |
| 2026-09-07 | Donald Bergstrom | President of Research & Development | Automatic Disposition | -8,530 | $18.97 |
| 2026-09-07 | Sanjiv Patel | Chief Executive Officer | Automatic Disposition | -48,199 | $18.94 |
| 2026-09-07 | Thomas Catinazzo | Chief Financial Officer | Automatic Disposition | -17,717 | $18.94 |
| 2026-08-25 | Peter Rahmer | Chief Corporate Development Officer | Automatic Disposition | -4,508 | $20.03 |
| 2026-08-24 | SoftBank Group Corp. | -- | Private Disposition | -6,000,000 | $19.40 |
| 2026-08-16 | Sanjiv Patel | Chief Executive Officer | Automatic Disposition | -48,199 | $20.33 |
| 2026-08-13 | Thomas Catinazzo | Chief Financial Officer | Automatic Disposition | -17,717 | $19.74 |
| 2026-08-03 | Sekar Kathiresan | Former Independent Director | Intent to Sell (Form 144) | -42,225 | $19.57 |
| 2026-07-30 | Sekar Kathiresan | Former Independent Director | Intent to Sell (Form 144) | -30,000 | $18.79 |
| 2026-07-27 | Donald Bergstrom | President of Research & Development | Open Market Disposition | -2,237 | $18.61 |
| 2026-07-27 | Peter Rahmer | Chief Corporate Development Officer | Open Market Disposition | -748 | $18.61 |
| 2026-07-27 | Thomas Catinazzo | Chief Financial Officer | Open Market Disposition | -1,459 | $18.61 |
| 2026-07-20 | Sekar Kathiresan | Former Independent Director | Intent to Sell (Form 144) | -30,000 | $19.81 |
| 2026-07-19 | Sekar Kathiresan | Former Independent Director | Intent to Sell (Form 144) | -66,055 | $19.58 |
| 2026-07-06 | Sanjiv Patel | Chief Executive Officer | Automatic Disposition | -48,199 | $19.58 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Relay Therapeutics discussion 0 comments